Estradiol Suppression and clinical outcomes in HR+ breast cancer

Megan Tesch, MD, Dana Farber Cancer Institute, Boston, MA, comments on endocrine outcomes and survival impacts of gonadotropin-releasing hormone agonist (GnRHa) treatment in young women with hormone receptor-positive breast cancer. Despite ovarian function suppression, estradiol levels were not sufficiently lowered in half of patients. The findings highlight the need for further research into optimizing estradiol suppression. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.